MedWatch

Ascendis Pharma's growth hormone formally approved in the EU

On Thursday, the European Commission has officially approved Ascendis Transcon hGH, which was given a positive recommendation from the European Medicines Agency.

Photo: Kevin Grønnemann / MedWatch

Following a positive recommendation from the European Medicines Agency (EMA), the European Commission has officially approved Ascendis Pharma's Lonapegsomatropin, Ascendis announces in a press release.

Lonapegsomatropin, which is developed under the name Transcon hGH and marketed in the US as Skytrofa, is a once-weekly injection for pediatric patients, and the approval follows a positive opinion from the EMA's expert committee, the CHMP, in November.

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs